ACTRN12606000238572
Recruiting
Phase 1
Feasibility and safety of erythropoietin (EPO) administration in patients with acute myocardial infarction (AMI) to improve cardiac function and remodelling.
Eastern Heart Clinic0 sites20 target enrollmentJune 14, 2006
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Acute Myocardial Infarction (AMI)
- Sponsor
- Eastern Heart Clinic
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Acute ST elevation myocardial infarction that are treated with primary angioplasty and stenting who have significant left ventricular (LV) impairment.
Exclusion Criteria
- •Multiple \- but particularly major comorbidities.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
To assess the effect of erythropoietin (EPO)in augmentation of peri implant tissues.Health Condition 1: K055- Other periodontal diseasesCTRI/2023/08/056074one
Terminated
Phase 2
Erythropoietin Spinal Cord Compression Randomized TrialNerve Compression SyndromesNCT00220675Sunnybrook Health Sciences Centre7
Completed
Phase 4
Impact of Recombinant Human Erythropoietin (ior EPO-CIM) in oncology pediatric patients with post chemo and /or radiotherapy.Anemia secondary to chemo and/or radiotherapy.RPCEC00000080Center of Molecular Immunology(CIM)161
Terminated
Phase 3
Renal Graft Function After Treatment With Erythropoietin (EPO)IschemiaNCT01450878University Hospital, Limoges6
Unknown
Phase 4
Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell TransplantationAnemiaLymphomaHematopoietic Stem Cell TransplantationNCT03010579Peking University70